- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gary Owens, MD, Talks About Trends in RA Management
Gary Owens, MD, Gary Owens Associates, says that trends in rheumatoid arthritis (RA) management are coming from the new 2012 American College of Rheumatology guidelines that call for earlier and more aggressive treatment of new patients as well as patients who are not doing well on existing therapies.
Gary Owens, MD, Gary Owens Associates, says that trends in rheumatoid arthritis (RA) management are coming from the new 2012 American College of Rheumatology guidelines that call for earlier and more aggressive treatment of new patients as well as patients who are not doing well on existing therapies. Dr Owens also discusses the drug costs associated with the treatment of RA. Health plans are looking to optimize value while managing cost.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
